News

24/7 Wall St.14h
Hims & Hers Shows It's More Than Just GLP-1 Drugs
Hims & Hers Health (NYSE:HIMS) reported first-quarter earnings on Monday after the market closed and rocketed 18% after ...
Hims & Hers: 2030 Guidance Indicates Big Upside
Hims & Hers management's 2030 guidance includes $6.5 billion in revenue and $1.3 billion in adjusted EBITDA. Read why HIMS ...
Hims & Hers: The Next Amazon? Novo Nordisk Might Be Prime Delivery
Hims & Hers Health Inc. (NYSE:HIMS) partners with Novo Nordisk to offer affordable weight-loss drug, positioning itself to ...
Novo Nordisk to sell Wegovy through telehealth firms to cash-paying US customers
Novo Nordisk said on Tuesday it was working with telehealth firms Hims & Hers , Ro and LifeMD to sell Wegovy, as it looks to ...
2 Reasons Hims & Hers Will Break $50s - Buy Post Earnings
Hims & Hers Health, Inc.'s subscriber growth, Novo Nordisk partnership, and FDA pill approval could boost financials. Click ...
The Cardiology Advisor11h
Novo Nordisk Partners With Telehealth Platforms to Expand Wegovy Access
Novo Nordisk is collaborating with multiple telehealth organizations in an effort to increase patient access to authentic ...
Novo Nordisk teams with telehealth firms Hims, Ro to sell Wegovy at lower price
Novo Nordisk A/S said it would sell its popular weight-loss drug Wegovy for a steeply reduced price on several telehealth ...
Health Care Up After Novo Nordisk Earnings -- Health Care Roundup
Novo Nordisk shares rose after the Danish obesity-drug maker's first-quarter earnings topped Wall Street expectations. As widely anticipated, the drug maker reduced its growth forecast to reflect the ...
How much a $1,000 investment in Hims & Hers at its IPO would be worth now
Hims & Hers stock has risen by 20% after announcing a partnership to sell the popular weight-loss drug Wegovy.